MarginsXMarginsX
Home › Markets › Health Care › ABUS

Arbutus Biopharma Corporation (ABUS)

ABUS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.04
-1.22% on the day
Market cap
$619.3M
Small cap
Revenue · 2025
$14.1M
+128.2% on 2024
Net income · 2025
-$33.5M
-237.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABUS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001447028
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2025

LineValue
Revenue$14.1M
Net income-$33.5M
Operating income-$38.2M
Net margin-237.9%
Operating margin-271.0%
Revenue growth+128.2%
Cash$18.0M
Total assets$94.6M
P/E (computed)Net income was not positive
P/S (computed)44.0×

Warning signs

Cash runway
Cash-flow positive
$264.2M cash at September 30, 2026
Share count, 1 year
-20.3%
2025-11-11 to 2026-11-06 · -8.6% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$264.2M cash; operating cash flow $55.3M a quarter.Report 2026-09-30
Shares outstanding153,292,826 (2026-11-06); 192,324,017 a year earlier; 167,695,247 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$299K$59.1M$239.8M$264.2M$0$181.5M10-Q 2026-11-10
Q2 2026
2026-06-30
$1.0M-$5.1M-$6.0M$19.2M$0$181.7M10-Q 2026-08-12
Q1 2026
2026-03-31
$179.1M$169.7M-$8.1M$23.7M$0$191.4M10-Q 2026-05-13
Q4 2025
2025-12-31
$1.1M-$3.8M-$4.7M$18.0M$0$14.1M10-K 2026-03-23
Q3 2025
2025-09-30
$529K-$7.7M-$5.8M$22.4M$0$14.6M10-Q 2026-11-10
Q2 2025
2025-06-30
$10.7M$2.5M-$15.7M$37.4M$0$15.4M10-Q 2026-08-12
Q1 2025
2025-03-31
$1.8M-$24.5M-$13.4M$37.1M$0$6.4M10-Q 2026-05-13
Q4 2024
2024-12-31
$1.6M-$12.5M-$10.3M$36.3M$0$6.2M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32024-11-06
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-10
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxyDEFA14A2026-04-14

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+11.7%
1 month-0.5%
3 months-10.7%
Year to date-15.0%
1 year-10.3%
From 52-week high-21.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
GERNGeron Corporation$0.9419-2.60%$606.8M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
KURAKura Oncology Inc.$7.09-8.75%$651.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier